Market Cap 189.66M
Revenue (ttm) 0.00
Net Income (ttm) -46.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 172,000
Avg Vol 827,456
Day's Range N/A - N/A
Shares Out 115.65M
Stochastic %K 86%
Beta 1.48
Analysts Strong Sell
Price Target $8.25

Company Profile

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
Latest News on NBP
NovaBridge Biosciences Slides: Company presentation

Apr 15, 2026, 7:00 AM EDT - 2 months ago

NovaBridge Biosciences Slides: Company presentation


NovaBridge Biosciences Earnings release: Q4 2025

Apr 7, 2026, 7:00 AM EDT - 2 months ago

NovaBridge Biosciences Earnings release: Q4 2025


NovaBridge Biosciences Annual report: Q4 2025

Apr 7, 2026, 7:00 AM EDT - 2 months ago

NovaBridge Biosciences Annual report: Q4 2025


NovaBridge Biosciences Transcript: Status update

Mar 9, 2026, 9:00 AM EDT - 4 months ago

NovaBridge Biosciences Transcript: Status update


NovaBridge Biosciences Press release: Status update

Mar 9, 2026, 9:00 AM EDT - 4 months ago

NovaBridge Biosciences Press release: Status update


NovaBridge Biosciences Slides: Status update

Mar 9, 2026, 9:00 AM EDT - 4 months ago

NovaBridge Biosciences Slides: Status update


NovaBridge Biosciences Slides: Investor presentation

Feb 23, 2026, 6:00 AM EST - 4 months ago

NovaBridge Biosciences Slides: Investor presentation


NovaBridge resumed with a Buy at H.C. Wainwright

2026-02-06T11:12:13.000Z - 5 months ago

NovaBridge resumed with a Buy at H.C. Wainwright


NovaBridge Biosciences Transcript: Investor Update

Oct 16, 2025, 4:45 PM EDT - 9 months ago

NovaBridge Biosciences Transcript: Investor Update


NovaBridge Biosciences Press release: Investor Update

Oct 16, 2025, 4:45 PM EDT - 9 months ago

NovaBridge Biosciences Press release: Investor Update


I-Mab to Participate in September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 11 months ago

I-Mab to Participate in September Investor Conferences


NovaBridge Biosciences Earnings release: Q2 2025

Aug 20, 2025, 7:00 AM EDT - 11 months ago

NovaBridge Biosciences Earnings release: Q2 2025


Everest Medicines Expands Strategic Investment in I-MAB

Aug 1, 2025, 8:56 AM EDT - 11 months ago

Everest Medicines Expands Strategic Investment in I-MAB